Published in J Clin Oncol on February 01, 1996
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol (2013) 2.50
How I treat CNS lymphomas. Blood (2013) 1.20
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res (2012) 1.07
Progress in central nervous system lymphomas. Br J Haematol (2014) 0.96
Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy. Mediterr J Hematol Infect Dis (2014) 0.90
Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. Br J Cancer (2001) 0.89
An Algorithm for the Preclinical Screening of Anticancer Drugs Effective against Brain Tumors. ISRN Pharmacol (2012) 0.80
Etoposide induces cell death via mitochondrial-dependent actions of p53. Cancer Cell Int (2015) 0.80
The Challenge of Primary Central Nervous System Lymphoma. Hematol Oncol Clin North Am (2016) 0.77
Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002. Ann Oncol (2013) 0.75
Reply to M.C. Chamberlain. J Clin Oncol (2014) 0.75
New approaches in primary central nervous system lymphoma. Chin Clin Oncol (2015) 0.75
Disease characteristics and survival outcomes of extragonadal primary germ cell tumour in two Canadian tertiary cancer centres. Can Urol Assoc J (2016) 0.75
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol (1996) 5.09
Common musculoskeletal tumors of childhood and adolescence. N Engl J Med (1999) 4.61
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med (2000) 3.77
High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Foreign-body perforation of the intestinal tract. Report of 12 cases and review of the literature. Arch Surg (1970) 3.26
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med (1995) 3.26
Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15
Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet (1998) 3.07
Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol (1995) 3.00
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 2.92
Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood (1995) 2.89
Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet (1993) 2.85
Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science (1991) 2.64
Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol (2004) 2.63
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia (1995) 2.54
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. Int J Radiat Oncol Biol Phys (2001) 2.44
Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A (1992) 2.41
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science (1998) 2.31
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
Juvenile myelomonocytic leukemia. Blood (1997) 2.19
Myeloid neoplasia in children treated for solid tumours. Lancet (1990) 2.18
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. Proc Natl Acad Sci U S A (1993) 2.12
The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma (2001) 2.10
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol (2001) 2.06
Pre-B-cell leukemia. A new phenotype of childhood lymphoblastic leukemia. N Engl J Med (1978) 2.05
Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys (1995) 2.01
Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med (1993) 1.99
Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Lipoprotein analysis in the evaluation of chest pain in the emergency department. Mayo Clin Proc (1991) 1.92
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations. Cancer Res (1991) 1.88
B lymphocyte precursors in human bone marrow: an analysis of normal individuals and patients with antibody-deficiency states. J Immunol (1978) 1.88
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia (2004) 1.87
Non-Hodgkin's lymphoma in childhood. N Engl J Med (1996) 1.83
Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol (2000) 1.83
Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med (1991) 1.83
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science (1987) 1.76
Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood (1991) 1.74
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood (1991) 1.73
Biological and therapeutic aspects of infant leukemia. Blood (2000) 1.70
Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med (1989) 1.69
Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67
Childhood adrenocortical tumors. J Clin Endocrinol Metab (1997) 1.64
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64
Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol (2001) 1.63
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60